MAPT and type 2 diabetes mellitus: A wider pancreatic tau immunoreactivity was found in patients with synucleinopathies than in controls (p < 0.0001), but we did not find differences in pancreatic tau between subjects with synucleinopathies and subjects with normal neuropathological examination and a history of T2DM (p = 0.2323, Fig. 1s).